SPRIM Global Investments ("SGI"), a global investment firm specializing in clinical-stage life sciences and pharma services based in Singapore, and One Investment Management ("OneIM"), a global alternative investment management firm, today announce a $300mn Joint Venture ("JV") to accelerate clinical trial financing.

The strategic partnership will fuel the expansion of SGI's specialized financing platform, TrialCap, a pioneering financing solution designed to support clinical trials from Phase 1 through Phase 3. With more than two decades of deep industry expertise, TrialCap offers flexible and innovative financial support to biotech and medtech companies, helping them advance groundbreaking therapies and accelerate time-to-market.  

Michael Shleifer, Co-Founder and Managing Partner of SPRIM Global Investments, said, "Our mission is to remove financial barriers that hinder biotech and medtech companies from focusing on research and development. Through this strategic partnership with OneIM, we are significantly expanding our ability to provide critical financing solutions that drive innovation in life sciences."

Matt Ross, Partner at OneIM, commented, "We see tremendous opportunities in the life sciences sector and are delighted to collaborate with SGI, a firm that has a proven track record, deep connectivity across the healthcare ecosystem and a strong pipeline of opportunities.  We look forward to accelerating the growth of this platform alongside Michael and the team."